|
1
|
Brasil. Instituto Nacional do Câncer.
Estimativas 2008: Incidência de Câncer no Brasil. Instituto
Nacional do Câncer, Rio de Janeiro; 2007
|
|
2
|
Beahrs O: Staging of cancer. CA Cancer J
Clin. 41:121–125. 1991. View Article : Google Scholar
|
|
3
|
Hortobagyi GN, Ames FC, Buzdar AU, et al:
Management of stage III primary breast cancer with primary
chemotherapy, surgery and radiation therapy. Cancer. 62:2507–2516.
1988. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hortobagyi GN, Spanos W, Montague E,
Buzdar AU, Yap HY and Blumenschein GR: Treatment of locoregionally
advanced breast cancer with surgery, radiotherapy and combination
chemoimmunotherapy. Int J Radiat Oncol Biol Phys. 9:643–650. 1983.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hortobagyi GN: Multidisciplinary
management of advanced primary and metastatic breast cancer.
Cancer. 74:S416–S423. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hortobagyi GN, Blumenschein GR, Spanos W,
Montague ED, Buzdar AU, Yap HY and Schell F: Multimodality
treatment of locoregionally advanced breast cancer. Cancer.
51:763–768. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Booser DJ and Hortobagyi GN: Treatment of
locally advanced breast cancer. Semin Oncol. 19:278–285.
1992.PubMed/NCBI
|
|
8
|
Hortobagyi GN: Comprehensive management of
locally advanced breast cancer. Cancer. 66:1387–1391. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Reubens RD, Bartelink H, Engelsman E, et
al: Locally advanced breast cancer: the contribution of cytotoxic
and endocrine treatment to radiotherapy. An EORTC breast cancer
co-operative trial (10792). Eur J Cancer. 25:667–678. 1989.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Swain SM, Sorace RA, Bagley CS, et al:
Neoadjuvant chemotherapy in the combined modality approach of
locally advanced nonmetastatic breast cancer. Cancer Res.
47:3889–3894. 1987.PubMed/NCBI
|
|
11
|
Feldman LD, Hortobaygi GN, Buzdar AU, Ames
FC and Blumenschein GR: Pathological assessment of response to
induction chemotherapy in breast cancer. Cancer Res. 46:2578–2581.
1986.PubMed/NCBI
|
|
12
|
Buzdar A, Montague E, Barker J, Hortobagyi
G and Blumenschein G: Management of inflammatory carcinoma of the
breast with combined modality approach – an update. Cancer.
47:2537–2542. 1981.
|
|
13
|
Smith IC, Heys SD, Hutcheon AW, et al:
Neoadjuvant chemotherapy in breast cancer: significantly enhanced
response with docetaxel. J Clin Oncol. 20:1456–1466. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dunnwald LK, Gralow JR, Ellis GK, et al:
Residual tumor uptake of [99mTc]-sestamibi after
neoadjuvant chemotherapy for locally advanced breast carcinoma
predicts survival. Cancer. 103:680–688. 2005.
|
|
15
|
Therasse P, Arbuck SG, Eisenhauer EA, et
al: New guidelines to evaluate the response to treatment in solid
tumors. J Natl Cancer Inst. 92:205–216. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wahl R, Zasadny K, Halvie M, Hutchins G,
Weber B and Cody R: Metabolic monitoring of breast cancer
chemohormonotherapy using positron emission tomography: initial
evaluation. J Clin Oncol. 11:2101–2111. 1993.
|
|
17
|
Abraham DC, Jones RC, Jones SE, et al:
Evaluation of neoadjuvant chemotherapeutic response of locally
advanced breast cancer by magnetic resonance imaging. Cancer.
78:91–100. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kedar RP, Cosgrove DO, Smith IE, Mansi JL
and Bamber JC: Breast carcinoma: measurement of tumor response to
primary medical therapy with color flow Doppler imaging. Radiology.
190:825–830. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Khalkhali I, Diggles LE, Taillefer R,
Vandestreek PR, Peller PJ and Abdel-Nabi HH: Procedure guideline
for breast scintigraphy. J Nucl Med. 40:1233–1235. 1999.PubMed/NCBI
|
|
20
|
Mankoff DA, Dunnwald LK, Gralow JR, Ellis
GK, Drucker MJ and Livingstone RB: Monitoring the response of
patients with locally advanced breast carcinoma to neoadjuvant
chemotherapy using [technetium 99m]-sestamibi scintimammography.
Cancer. 85:2410–2423. 1999.
|
|
21
|
Khalkhali I, Mena I and Jouanne E: Prone
scintimammography in patients with suspicion of breast cancer. J Am
Coll Surg. 78:491–497. 1994.
|
|
22
|
Diggles L, Mena I and Khalkhali I:
Technical aspects of prone dependent-breast scintimammography. J
Nucl Med Tech. 22:165–170. 1994.
|
|
23
|
Del Vecchio S, Zannetti A, Fonti R,
Iommelli F and Salvatore M: 99mTc-MIBI in the evaluation
of breast cancer biology. Breast Cancer Nuclear Medicine in
Diagnosis and Therapeutic Options. Bombardieri E, Bonadonna G and
Gianni L: Springer; Berlin: pp. 71–81. 2008
|
|
24
|
Del Vecchio S, Zannetti A, Aloj L, Caraco
C, Ciarmiello A and Salvatore M: Inhibition of early
99mTc-MIBI uptake by Bcl-2 anti-apoptotic protein
overexpression in untreated breast carcinoma. Eur J Nucl Med Mol
Imaging. 30:879–887. 2003.
|
|
25
|
Marshall C, Eremin J, Mohammed ES, Eremin
O and Griffiths A: Monitoring the response of large (>3 cm) and
locally advanced (T3-4, N0-2) breast cancer to neoadjuvant
chemotherapy using 99mTc-sestamibi uptake. Nucl Med
Commun. 26:9–15. 2005.
|
|
26
|
Cwikla JB, Buscombe JR, Barlow RV, et al:
The effect of chemotherapy on the uptake of technetium-99m
sestamibi in breast cancer. Eur J Nucl Med. 24:1175–1178.
1997.PubMed/NCBI
|
|
27
|
Wilczek B, Von Schoultz E, Bergh J,
Eriksson E, Larsson SA and Jacobsson H: Early assessment of
neoadjuvant chemotherapy by FEC-courses of locally advanced breast
cancer using 99mTc-MIBI. Acta Radiol. 43:284–287. 2003.
View Article : Google Scholar : PubMed/NCBI
|
